Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 6;8(4):287-296.
doi: 10.1002/wjo2.57. Online ahead of print.

Otologic and vestibular symptoms in COVID-19: A scoping review

Kimberly Mae C Ong  1   2 , Teresa Luisa G Cruz  1   2   3
Affiliations
Review

Otologic and vestibular symptoms in COVID-19: A scoping review

Kimberly Mae C Ong et al. World J Otorhinolaryngol Head Neck Surg. .

Abstract

Background: Otologic and vestibular symptoms have been seen in patients confirmed to have COVID-19 disease. Further discussion of these symptoms may provide insight into short- and long-term management for these patients.

Objective: The aim of this review was to describe the otologic and vestibular symptoms that present in patients with COVID-19. The primary outcomes of this review were onset, duration and clinical outcomes of these symptoms.

Sources of evidence: Pub Med, APAMed Central, Herdin, CINAHL, Scopus, Springer Link, ProQuest Coronavirus Research Database, and Google Scholar were searched for the articles to be included.

Eligibility criteria: Studies included were those involving adult patients diagnosed with COVID-19 who experienced hearing loss, ear pain, ear discharge, otitis media, vertigo, or tinnitus. Studies were eligible for inclusion if there was a description of the otologic dysfunction, specifically onset, duration, or clinical outcomes.

Results: The majority of patients who experienced hearing loss (68%), tinnitus (88%), vertigo/dizziness (30%), ear pain (8%), and discharge (100%) did so within a month of experiencing the typical symptoms of COVID-19. A majority also experienced complete resolution of their symptoms within 2 weeks. Standard treatment for COVID-19 was usually provided but when specific diagnoses are made for these symptoms (e.g., sudden sensorineural hearing loss, otitis media, vestibular neuritis), they are treated in the same manner as one would for non-COVID-19 cases, in addition to the management for COVID-19. In certain cases, there may be a need for additional work-up to rule out other causes.

Conclusions: Otologic and vestibular symptoms were present in COVID-19 patients, majority as part of the systemic nature of the disease. The onset, duration, and course were consistent with the natural history of a systemic viral infection. COVID-19 should be considered in any patient with a new-onset hearing loss, tinnitus, or vertigo/dizziness, even in the absence of infectious or respiratory symptoms.

Keywords: COVID‐19; dizziness; hearing loss; tinnitus; vertigo.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram for study selection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Analysis of characteristics of and risk factors for otological symptoms after COVID-19 infection.
    Wang Q, Gu H, Ren J, Zhao Y, Meng Z. Wang Q, et al. PLoS One. 2024 Feb 1;19(2):e0297100. doi: 10.1371/journal.pone.0297100. eCollection 2024. PLoS One. 2024. PMID: 38300969 Free PMC article.
  • An online survey on clinical characteristics of otologic symptoms linked to COVID-19 infection.
    Wu L, Peng H, He Y, Pu L, Zhong S. Wu L, et al. Front Public Health. 2023 May 26;11:1184262. doi: 10.3389/fpubh.2023.1184262. eCollection 2023. Front Public Health. 2023. PMID: 37304124 Free PMC article.
  • Increased Incidence of Vestibular Disorders in Patients With SARS-CoV-2.
    Lee L, French E, Coelho DH, Manzoor NF; N3C consortium.; Wilcox AB, Lee AM, Graves A, Anzalone A, Manna A, Saha A, Olex A, Zhou A, Williams AE, Southerland A, Girvin AT, Walden A, Sharathkumar AA, Amor B, Bates B, Hendricks B, Patel B, Alexander C, Bramante C, Ward-Caviness C, Madlock-Brown C, Suver C, Chute C, Dillon C, Wu C, Schmitt C, Takemoto C, Housman D, Gabriel D, Eichmann DA, Mazzotti D, Brown D, Boudreau E, Hill E, Zampino E, Marti EC, Pfaff ER, French E, Koraishy FM, Mariona F, Prior F, Sokos G, Martin G, Lehmann H, Spratt H, Mehta H, Liu H, Sidky H, Awori Hayanga JW, Pincavitch J, Clark J, Harper JR, Islam J, Ge J, Gagnier J, Saltz JH, Saltz J, Loomba J, Buse J, Mathew J, Rutter JL, McMurry JA, Guinney J, Starren J, Crowley K, Bradwell KR, Walters KM, Wilkins K, Gersing KR, Cato KD, Murray K, Kostka K, Northington L, Pyles LA, Misquitta L, Cottrell L, Portilla L, Deacy M, Bissell MM, Clark M, Emmett M, Saltz MM, Palchuk MB, Haendel MA, Adams M, Temple-O'Connor M, Kurilla MG, Morris M, Qureshi N, Safdar N, Garbarini N, Sharafeldin N, Sadan O, Francis PA, Burgoon PW, Robinson P, Payne PRO, Fuentes R, Jawa R, Erwin-Cohen R, Patel R, Moffitt RA, Zhu RL, Kamaleswaran R, Hurl… See abstract for full author list ➔ Lee L, et al. Otol Neurotol Open. 2024 Apr 2;4(2):e051. doi: 10.1097/ONO.0000000000000051. eCollection 2024 Jun. Otol Neurotol Open. 2024. PMID: 38919767 Free PMC article.
  • Clinical Profile and Outcome Analysis of Ear-Nose-Throat Symptoms in SARS-CoV-2 Omicron Subvariant Infections.
    Liu Y, Huang X, Li P, Wang D, Yin H, Wang N, Luo Y, Li H, Sun S. Liu Y, et al. Int J Public Health. 2023 Oct 10;68:1606403. doi: 10.3389/ijph.2023.1606403. eCollection 2023. Int J Public Health. 2023. PMID: 37920846 Free PMC article.
  • Acute labyrinthitis: a manifestation of COVID-19 in a teenager.
    Saniasiaya J, Kulasegarah J. Saniasiaya J, et al. BMJ Case Rep. 2023 Dec 28;16(12):e258290. doi: 10.1136/bcr-2023-258290. BMJ Case Rep. 2023. PMID: 38154869
See all "Cited by" articles

References

    1. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS‐CoV‐2; COVID‐19): a systematic review and meta‐analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765. 10.1371/journal.pone.0234765 - DOI - PMC - PubMed
    1. El‐Anwar MW, Elzayat S, Fouad YA. ENT manifestation in COVID‐19 patients. Auris Nasus Larynx. 2020;47(4):559‐564. 10.1016/j.anl.2020.06.003 - DOI - PMC - PubMed
    1. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS‐CoV‐2, COVID‐19 and audio‐vestibular symptoms. Int J Audiol. 2021;60(12):935‐945. 10.1080/14992027.2021.1896793 - DOI - PubMed
    1. Maharaj S, Bello Alvarez M, Mungul S, Hari K. Otologic dysfunction in patients with COVID‐19: a systematic review. Laryngoscope Investig Otolaryngol. 2020;5(6):1192‐1196. 10.1002/lio2.498 - DOI - PMC - PubMed
    1. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA‐ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467‐473. 10.7326/M18-0850 - DOI - PubMed